Zobrazeno 1 - 10
of 259
pro vyhledávání: '"SC Linn"'
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Many scientific papers are published each year and substantial resources are spent to develop biomarker-based tests for precision oncology. However, only a handful of tests is currently used in daily clinical practice, since devel
Externí odkaz:
https://doaj.org/article/45f2bcb68846479796b0efe94f7d875e
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/b70066ba08084dfb929cda2e5cc6e7f9
Autor:
A Jager, M Jongen-Lavrencic, JP Lotz, A Gonçalves, M Graeser, U Nitz, IAM Mandjes, MJ Holtkamp, M Schot, VP Retel, EJ Kuip, ANM Wymenga, IR Konings, VCG Tjan-Heijnen, JR Kroep, CP Schrӧder, E Van Der Wall, Sc Linn, S Vliek
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3389d18e6873ca9ee30fb022f95fc593
Autor:
M.J. van de Vijver, Marieke A. Vollebergh, L. Wessels, E.G.E. de Vries, Sjoerd Rodenhuis, Jelle Wesseling, Petra M. Nederlof, Michael Hauptmann, Sc. Linn
Publikováno v:
Cancer Research. 70:PD01-04
Background: Breast cancer cells deficient for BRCA1 are hypersensitive to agents eventually resulting in double-strand DNA breaks, such as platinating agents and poly(ADP-ribose)polymerase (PARP)-inhibitors. Using a BRCA1 array comparative genomic hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4de77e198234b8d75466661578d8860
https://doi.org/10.1158/0008-5472.sabcs10-pd01-04
https://doi.org/10.1158/0008-5472.sabcs10-pd01-04
Publikováno v:
Cancer Research. 76:S6-06
Background Since the addition of trastuzumab to (neo)adjuvant chemotherapy, the prognosis of patients with stage II and III HER2-positive breast cancer has significantly improved. Several reports have subsequently shown that small, node-negative tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f388e02e7df021b2c4908ae26d3f05c
https://doi.org/10.1158/1538-7445.sabcs15-s6-06
https://doi.org/10.1158/1538-7445.sabcs15-s6-06
Autor:
Judith Kroep, Sc, Linn, Boven E, Hj, Bloemendal, Baas J, Ia, Mandjes, van den Bosch J, Wm, Smit, de Graaf H, Cp, Schröder, Gj, Vermeulen, Wc, Hop, Jw, Nortier
Publikováno v:
Europe PubMed Central
Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens. We presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5527fa125abef75c15c329e546cab515
https://pubmed.ncbi.nlm.nih.gov/20876920
https://pubmed.ncbi.nlm.nih.gov/20876920
Autor:
Feller N, Hoekman K, Cm, Kuiper, Sc, Linn, Henk Verheul, Bg, Wolthers, Popp-Snijders C, Hm, Pinedo
Publikováno v:
Europe PubMed Central
We describe a patient with a metastasized adrenocortical cancer who exhibited excessive production of both glucocorticoids and mineralocorticoids combined with suppressed androgen production. Unusual steroid metabolites found in the patient's urine h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::64977adc3e62ac66da4ab367b9596a9c
http://europepmc.org/abstract/med/9815696
http://europepmc.org/abstract/med/9815696
Autor:
van Ommen-Nijhof A; Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands., Steenbruggen TG; Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands; Department of internal medicine, St Antonius hospital, Nieuwegein, the Netherlands., Wiersma TG; Department of radiotherapy, NKI-AVL, Amsterdam, the Netherlands., Balduzzi S; Department of biometrics, NKI-AVL, Amsterdam, the Netherlands., Daletzakis A; Department of biometrics, NKI-AVL, Amsterdam, the Netherlands., Holtkamp MJ; Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands., Delfos M; Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands., Schot M; Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands., Beelen K; Department of internal medicine, Rijnstate, Arnhem, the Netherlands., Siemerink EJM; Department of internal medicine, Ziekenhuisgroep Twente, Almelo, Hengelo, the Netherlands., Heijns J; Department of internal medicine, Amphia, Breda, the Netherlands., Mandjes IA; Department of biometrics, NKI-AVL, Amsterdam, the Netherlands., Wesseling J; Department of pathology, NKI-AVL, Amsterdam, the Netherlands; Department of pathology, LUMC, Leiden, the Netherlands., Rosenberg EH; Department of pathology, NKI-AVL, Amsterdam, the Netherlands., Vrancken Peeters MJT; Department of surgical oncology, NKI-AVL, Amsterdam, the Netherlands; Department of surgical oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands., Linn SC; Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands; Department of pathology, Utrecht University, Utrecht, the Netherlands., Sonke GS; Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands; Department of medical oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands. Electronic address: g.sonke@nki.nl.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Dec; Vol. 213, pp. 115083. Date of Electronic Publication: 2024 Oct 20.
Autor:
Nederlof I; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Isaeva OI; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Graaf M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Gielen RCAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bakker NAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Rolfes AL; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Garner H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Boeckx B; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Traets JJH; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Maaker M; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Brussel T; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Chelushkin M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Champanhet E; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lopez-Yurda M; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van de Vijver K; Department of Pathology, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium.; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Berg JG; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Klioueva N; Department of Pathology, OLVG Hospital, Amsterdam, the Netherlands., Mann RM; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Duijnhoven FH; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Skinner V; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Luykx S; Medical Oncology Department, Tergooi Hospital - locatie Hilversum, Hilversum, the Netherlands., Kerver E; Department of Oncology, OLVG Hospital, Amsterdam, the Netherlands., Kalashnikova E; Natera, San Carlos, CA, USA., van Dongen MGJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Linn SC; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Visser KE; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands., Salgado R; Department of Pathology, ZAS hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Wessels LFA; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Drukker CA; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schumacher TN; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lambrechts D; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Kok M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.
Publikováno v:
Nature medicine [Nat Med] 2024 Nov; Vol. 30 (11), pp. 3223-3235. Date of Electronic Publication: 2024 Sep 16.
Autor:
Barbosa LN; Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America., LIanes A; Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Panama City, Panama., Madesh S; Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America., Fayne BN; Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America., Brangulis K; Latvian Biomedical Research and Study Centre, Riga, Latvia., Linn-Peirano SC; Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America., Rajeev S; Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America.
Publikováno v:
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2024 Sep 23; Vol. 18 (9), pp. e0012155. Date of Electronic Publication: 2024 Sep 23 (Print Publication: 2024).